MAY 15·openPR.com▼
Investigation Alert: Investors who hold shares of Inovio
An investigation has been launched by the Shareholders Foundation on behalf of long-term investors in Inovio Pharmaceuticals, Inc. (NASDAQ: INO) regarding potential breaches of fiduciary duties by certain directors. This follows a lawsuit alleging securities law violations after INO's share price plummeted due to delays in FDA submissions for its lead product candidate, INO-3107, and issues with its CELLECTRA device. The investigation concerns whether Inovio directors are liable for false or misleading statements regarding manufacturing, submission timelines, and regulatory prospects.
MAY 14·Stock Titan→
INOVIO (NASDAQ: INO) details Q1 loss and INO-3107 accelerated FDA review
INOVIO reported a net loss of $19.7 million for Q1 2026, consistent with the previous year, while significantly reducing operating expenses. The company's lead candidate, INO-3107, is under accelerated FDA review for recurrent respiratory papillomatosis, with a target PDUFA date of October 30, 2026, and INOVIO is preparing for a potential 2026 commercial launch. INOVIO projects its current cash, supplemented by recent equity offering proceeds, will fund operations into Q1 2027, beyond the FDA's decision date for INO-3107.
